Preoperative Smoking Cessation in Patients Undergoing Surgery
Launched by LUZERNER KANTONSSPITAL · Jan 1, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a special program to help people quit smoking before surgery can affect their recovery. Smokers who are about to undergo intermediate or high-risk surgeries, like those for abdominal, thoracic, or cancer-related conditions, might have a better chance of healing with this program. The study will compare two groups: one group will receive a comprehensive smoking cessation support program starting four weeks before their surgery, while the other group will only receive standard advice about quitting smoking. The researchers hope that those who participate in the smoking cessation program will experience fewer complications after surgery.
To be eligible for this trial, participants must be at least 18 years old, currently smoke daily, and be scheduled for certain types of surgeries at the Kantonsspital of Lucerne. Participants will be randomly assigned to one of the two groups and will be monitored for up to 90 days after their surgery to see how well they recover and whether they can quit smoking. This study is important because it addresses a missed opportunity to help smokers improve their health outcomes before surgery, which can also reduce hospital costs.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient listed for intermediate or high-risk surgery at the Kantonsspital of Lucerne
- • Patient undergoing surgery in one of the following departments: Abdominal surgery, thoracic surgery, cardiac surgery, urology, gynaecology, vascular surgery or head and neck surgery
- • Date of surgery \>2 weeks after date of listing for surgery or discussion by tumor board
- • Current smokers, defined as daily smoking of at least one cigarette, cigar or pipe
- • Age over 18 years
- • Able to give signed written informed consent
- Exclusion Criteria:
- • Plastic surgery
- • Consumption of illegal drugs
- • Alcohol dependency defined as preexisting alcohol related disorders (eg. alcoholic psychosis, Alcohol abuse, Alcohol polyneuropathy, degeneration of nervous system due to alcohol, Alcoholic myopathy, Alcoholic liver disease)
- • Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia
About Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) is a leading academic hospital located in Lucerne, Switzerland, dedicated to providing high-quality healthcare and advancing medical research. As a prominent clinical trial sponsor, LUKS is committed to fostering innovation in medical treatments and therapies through rigorous clinical studies. The institution emphasizes collaboration with multidisciplinary teams of healthcare professionals, researchers, and academic partners to ensure that its trials adhere to the highest ethical standards and regulatory requirements. With a focus on improving patient outcomes, LUKS leverages its state-of-the-art facilities and expertise to contribute significantly to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Luzern, , Switzerland
Patients applied
Trial Officials
Christian Fankhauser, PD Dr. med.
Principal Investigator
Klinik für Urologie, Luzerner Kantonsspital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials